Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1 through 6 canceled.

7. (Currently Amended) A method of ~~preventing guided navigation of endothelial tubes during angiogenesis to a target cell mass~~ inhibiting migration human microvascular endothelial cells (HMVECs) expressing a native Robo-4 receptor, ~~wherein said endothelial tubes express a Robo-4 receptor,~~ the method comprising ~~activating said Robo-4 receptor, wherein activating said Robo-4 receptor~~ exposing said HMVECs to a Slit ligand, wherein exposing said HMVECs to said Slit ligand inhibits ~~the guided navigation of the endothelial tubes toward the target cell mass~~ migration of said HMVECs.

8. (Currently Amended) The method of claim 7, wherein ~~activating said Robo-4 receptor comprises providing a ligand capable of activating said Robo-4 receptor and exposing said endothelial tubes to the ligand, wherein said exposure of said endothelial tubes to said ligand inhibits the guided navigation of the endothelial tubes toward the target cell mass~~ exposing said HMVECs to a Slit ligand comprises exposing said HMVECs to a Slit2 ligand.

9. (Currently Amended) The method of claim 8, wherein ~~providing a ligand capable of activating said Robo-4 receptor comprises providing a Slit~~ exposing said HMVECs to a Slit2 ligand comprises exposing said HMVECs to a human Slit2 ligand or a HMVEC migration inhibiting fragment thereof.

Claims 10 through 18 canceled.

19. (Currently Amended) A method of preventing angiogenesis by HMVECs ~~in endothelium tissue expressing Robo-4 receptor~~, the method comprising, ~~activating said Robo-4 receptor, wherein activating said Robo-4 receptor inhibits migration of endothelial cells~~ inhibiting migration of HMVECs expressing a native Robo-4 receptor, wherein inhibiting migration of said HMVECs comprises providing a Slit ligand and exposing said HMVECs to said Slit ligand such that migration of said HMVECs is inhibited

20. (Currently Amended) The method of claim 19, wherein ~~activating said Robo-4 receptor comprises providing a ligand capable of activating said Robo-4 receptor and exposing the endothelium tissue to the ligand, wherein said exposure of said endothelium tissue to said ligand inhibits migration of endothelial cells~~ providing a Slit ligand comprises providing a Slit2 ligand.

21. (Currently Amended) The method of claim 20, wherein ~~providing a ligand capable of activating said Robo-4 receptor~~ providing a Slit2 ligand comprises ~~providing a Slit ligand~~ providing a human Slit2 ligand or a HMVEC migration inhibiting fragment thereof.

Claim 22 canceled.